JuLiao Completes Nearly RMB 10 Million Angel Funding Round to Advance Integrated Medical-Educational Rehabilitation for Children with Neurodevelopmental Disorders

VCBeat has learned at the earliest opportunity that, focusing on the field of personalized integration of medical and educational services for children with neurodevelopmental disorders such as autism, attention deficit hyperactivity disorder (ADHD), and developmental delays,Zhejiang Juyi Hospital Management Co., Ltd.(abbreviated as"Juyi") has recently officially completed an angel round of financing worth nearly 10 million RMB. This round of financing was led byZelun CapitalSole Lead Investor,ROBE CAPITALServed as the exclusive financial advisor for this round of financing.

The funds raised will be allocated to autism subtyping, mechanistic research, the establishment of integrated medical-educational rehabilitation centers, and team building, thereby providing robust support for Juyi’s action agenda of “Immediate Launch to Help Children with Special Needs Return to Normal Life.”

Although Juyi was founded in 2019, it had already begun exploring comprehensive rehabilitation models for neurodevelopmental disorders such as autism spectrum disorder as early as 2017. Juyi holds that neurodevelopmental conditions—including autism spectrum disorder, global developmental delay, and attention-deficit/hyperactivity disorder (ADHD)—are behavioral abnormalities resulting from brain dysfunction, rather than brain dysfunction caused by behavioral abnormalities. Relying solely on special education is insufficient to address brain dysfunction. Although educational interventions can also shape neural networks,However, it is undoubtedly inefficient, and even ineffective for most children with autism, until deeper underlying health issues are addressed.

Current approaches that intervene solely at the behavioral level struggle to achieve ideal therapeutic outcomes. “In particular, among children with autism who have undergone three to four years of behavioral intervention, hardly any are capable of attending primary school independently; after more than a decade of such intervention, the rate of competitive employment is nearly zero; and even after thirty years of intervention, only a rare few can manage their daily lives and achieve independence. This has led parents of children with autism to commonly express the wish to ‘outlive their child by just one day,’” said Hu Jiayang, General Manager of Juyi. He explained that this is because the body and brain function as an integrated whole, just as behavior and cognition are inseparable; they cannot be viewed in isolation. To effectively address these challenges, interventions must target deeper underlying causes through a systematic, integrated approach combining medical care, rehabilitation, health maintenance, and education. Based on this principle, Juyi has developed an integrated comprehensive rehabilitation system that unifies “medical care, rehabilitation, education, and caregiving.”

Over the four years since its establishment, Juyi has provided interventions for nearly 1,000 children with autism. Under the integrated model of medical care, rehabilitation, and education, the improvement rate for core symptoms of autism exceeds 90%, with 52% of children showing significant improvement and 12% demonstrating remarkable improvement, enabling their reintegration into mainstream education.

“Relying on a single rehabilitation method is undoubtedly one-sided; integrated comprehensive rehabilitation within the framework of integrative medicine is the inevitable trend for future autism rehabilitation.” Hu Jiayang, General Manager of Juyi Therapy, believes that autism is a complex disease with multiple etiologies and requires a holistic, comprehensive approach to rehabilitation.

For neurodevelopmental disorders such as autism, there are numerous etiologies. According to Hu Jiayang, while simple diseases may also have multiple causes, a single decisive factor typically triggers the disease; therefore, treatment with a single specific drug, such as penicillin, is often effective. In contrast, complex diseases are usually caused by the combined effect of multiple factors, without any single decisive cause. Consequently, monotherapy tends to be ineffective, and better therapeutic outcomes can only be achieved through precise, systematic approaches that identify multiple etiologies and implement multi-dimensional, multi-target interventions.

Juyi has mapped out the causal hierarchy of autism, enabling more targeted treatments at each level and thereby achieving superior therapeutic outcomes. The Juyi app employs a holistic medical approach, with its efficacy validated in the rehabilitation of autism, ADHD, and developmental delays.

Juyi Environment

Thanks to years of exploration, Juyi has developed mature solutions in the medical, rehabilitative, nursing, and educational care of autism. All rehabilitation centers under Juyi adopt a fully systematic service model integrating medical treatment, rehabilitation, nursing, and education. At Juyi Rehabilitation Centers, children with autism and other special needs not only receive high-quality special education but also benefit from one-stop comprehensive services encompassing medical care, rehabilitative medicine, and family caregiving support.

Medical Area

Rehabilitation Area

Dining Area

Laboratory

The greatest distinction between Juyi and other current pediatric rehabilitation institutions lies in its specialized medical service system, which includes functional medicine testing, microbiome therapy, nutritional therapy, and immunotherapy. By aligning with the characteristics of developmental disorders, implementing subtype-specific treatments, and providing comprehensive, personalized services that address issues at the medical level, Juyi has achieved significant therapeutic efficacy.

Among these, the distinctive microbiome-based therapies have gained recognition from numerous Grade 3A hospitals across China and established clinical research collaborations with institutions such as the Chinese PLA General Hospital (301 Hospital), Qilu Hospital of Shandong University, and Beijing Children's Hospital.

Possessing a comprehensive system integrating medical care, health management, rehabilitation, and education, it isJuyi’s Differentiated Advantages. Juyi’s profit model is not confined to special education tuition fees; instead, it can collaborate with all special-needs children’s rehabilitation institutions across China to export a comprehensive integrated model encompassing medical care, health management, rehabilitation, and education.

Under the integrated model of medical care, rehabilitation, elderly care, and education, partner institutions can not only retain their original profit channels but also leverage medical, rehabilitation, and elderly care services and products to generate new revenue streams.

Under the integrated model of medical care, health management, rehabilitation, and education, parents receive systematic support, thereby avoiding the tendency to “recognize only the teacher rather than the institution.””, the operational risks of special education institutions will also be significantly reduced.

Under the integrated model of medical care, health management, rehabilitation, and education, rehabilitation becomes more goal-oriented and logical, with clearer therapeutic outcomes. This undoubtedly enhances the enrollment capacity of partner institutions and attracts higher-quality clientele.

After four years of development, Juyi has established five rehabilitation centers across China, serving over 1,000 children annually and reaching more special-needs families with an annual growth rate exceeding 50%. The company has successfully developed its integrated model combining medical care, health management, rehabilitation, and education.In the future, we will roll out our comprehensive system, actively collaborate with other institutions, and achieve rapid channel expansion. We aim to become a medical service partner, teaching and research product supplier, and nutritional support provider for numerous rehabilitation institutions serving children with special needs in China.

Regarding this financing,Dr. Shao Jianzhong, Founder of JuyiHe stated, “This financing round has introduced industry investors such as Dr. Weng Xinghe, who specializes in neurobiology. With the acceleration driven by this round of funding, we aim to develop globally leading products and services in the field of autism through an integrated approach combining personalized traditional Chinese and Western medicine, medical care with education and wellness, and a four-in-one model integrating services, products, technology, and scientific research, thereby making it a reality for children with autism to recover normal function.”

Dr. Weng Xinghe, Manager of Zelun CapitalIt indicates that the prevalence of autism spectrum disorder (ASD) has been increasing year by year, imposing heavy emotional and financial burdens on families and society, with substantial unmet social needs. However, due to its complex etiology, the supply of rehabilitative therapies from related industries falls far short of family demands. Over the past decade, significant progress has been made in basic neurodevelopmental research on ASD, providing important insights and new perspectives for understanding and treating the condition. The Juyi team was among the first in China to conduct clinical explorations in this field. Over the past ten years, the team has closely followed international academic frontiers while remaining grounded in practice, accumulating extensive clinical experience and achieving favorable rehabilitation outcomes for pediatric patients, thereby earning recognition from both parents and industry experts.

Juyi focuses on its core business, with a clear profit model and fully demonstrated competitive capabilities, positioning it at the forefront of domestic innovation in autism rehabilitation. Internationally, similar to Juyi, by connecting doctors, therapists, parents, children, and the broader community,U.S.-based Cortica, which provides personalized diagnosis and treatment plans for children with neurodiversity, completed a $75 million Series D financing round in April this year., indicating that this sector is receiving significant attention from investors. We believe that Juyi will undoubtedly emerge as an internationally influential leader in this field.

Huang Guangjie, Partner at ROBE CAPITALIt stated that with economic development and advancements in medical care, societal attention to rehabilitation-related conditions for children with neurodevelopmental disorders has been increasingly growing, leading to rapid expansion in the market size of related products and services. As an innovative enterprise, Juyi’s ability to secure financing against the current capital market trends is attributable to its integrated “medical-educational-care-rehabilitation” system. By targeting substantial unmet clinical needs, Juyi provides systematic and personalized solutions for pediatric patients and their parents, thereby establishing a diversified commercial closed loop and ecosystem. We believe that with additional capital infusion, Juyi will undoubtedly accelerate its development trajectory, benefiting a broader population of children with autism and other special needs.

Zelun Capital focuses on investing in companies within the pharmaceutical, healthcare, and broader health industries that possess core competencies in technology, products, and teams, along with standardized corporate governance and significant growth potential. The core management team of Zelun has over 10 years of experience in technology investment, having witnessed China’s technological development firsthand and maintaining clear insights into industry trends. Focusing on early-stage and growth-stage investments, Zelun is committed to long-term discovery and promotion of technological innovation and entrepreneurship in China, striving to become a globally influential technology investment institution. Dr. Weng Xinghe, the fund manager, holds a Master’s degree in Neurobiology from Peking University and a Ph.D. in Cell Physiology from Cornell University. He has long been engaged in primary market investments, covering sectors such as fintech, integrated circuits, manufacturing equipment, healthcare, and consumer goods. He previously worked at Boston Consulting Group (BCG) in the United States.

ROBE CAPITAL, established in 2017, is a boutique investment bank specializing in healthcare and life sciences. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. The founding team hails from leading private equity firms, financial advisory institutions, management consulting companies, and vertical healthcare media outlets. Since its inception, ROBE CAPITAL has consistently completed double-digit private financing and M&A transactions annually, with cumulative transaction value exceeding RMB 10 billion. The firm’s team also boasts extensive industry expertise in providing value-added services to portfolio companies. In 2020, ROBE New Healthcare Fund was launched and has since invested in multiple leading companies within the sector.